e-Drug3D

1648

M TRAVOPROST


INN
TRAVOPROST

(is an active metabolite)

cas 54276-17-4
CLASS

SENSORY
ANTIHYPERTENSIVE
ANTIGLAUCOMA
OPHTHALMOLOGICALS
PROSTAGLANDIN ANALOGUES
FP PROSTANOID RECEPTOR AGONIST

ROUTE (list)

-

ATC code

S01EE04

PK parameters

Tmax 0.5 HOUR
Cmax 0.04 NANOMOLAR
t1/2 0.75 HOUR

Target

TARGET FP PROSTANOID RECEPTOR

DrugCentral

Prostaglandin F2-alpha receptor UNIPROT P43088 PTGFR

Download SDF file 5-Heptenoic acid, 7-[(1R,2R,3R,5S)-3,5-dihydroxy-2-[(1E,3R)-3-hydroxy-4-[3-(trifluoromethyl)phenoxy]-1-buten-1-yl]cyclopentyl]-, (5Z)-

Formula:
C23H29F3O6

Calculated chemical properties:

MW 457.45
NB_atoms 32
XLogP 2.23
PSA 106.529
NB_HD 3
NB_HA 6
fsp3 0.52
Lipinski(0=no;1=yes) 1

FDA
-

Other links:

PubChem
ChemicalProbes

U.S. repository of Clinical Trials

VigiAccess
SIDER side effects

ChemSynthesis
Patent@SureChEMBL

e-Drug3D

872

TRAVOPROST


INN
TRAVOPROST

(has an active metabolite)

cas 157283-68-6
CLASS

SENSORY
ANTIHYPERTENSIVE
ANTIGLAUCOMA
OPHTHALMOLOGICALS
PROSTAGLANDIN ANALOGUES
FP PROSTANOID RECEPTOR AGONIST
HYDROLYZED TO THE ACTIVE FREE ACID

ROUTE (list)

OPHTHALMIC INTRACAMERAL

ATC code

S01EE04

PK parameters

Solubility

PRACTICALLY INSOLUBLE IN WATER


Target

TARGET FP PROSTANOID RECEPTOR

DrugCentral

Prostaglandin F2-alpha receptor UNIPROT P43088 PTGFR

Download SDF file propan-2-yl (Z)-7-[(1R,2R,3R,5S)-3,5-dihydroxy-2-[(E,3R)-3-hydroxy-4-[3-(trifluoromethyl)phenoxy]but-1-enyl]cyclopentyl]hept-5-enoate

Formula:
C26H35F3O6

Calculated chemical properties:

MW 500.54
NB_atoms 35
XLogP 4.43
PSA 96.337
NB_HD 3
NB_HA 6
fsp3 0.58
Lipinski(0=no;1=yes) 0

FDA
NDA 021257 (label) INN (TRAVOPROST) TRAVATAN (ALCON PHARMS LTD) APPROVAL= AP YEAR= 2001 NEWMOLECULARENTITY DISCONTINUED
NDA 021994 (label) INN (TRAVOPROST) TRAVATAN Z (SANDOZ) APPROVAL= AP YEAR= 2006
NDA 091341 (pdf not found) INN (TRAVOPROST) TRAVOPROST (PAR PHARM) APPROVAL= TA YEAR= 2011
NDA 091340 (pdf not found) INN (TRAVOPROST) TRAVOPROST (CHARTWELL RX) APPROVAL= AP YEAR= 2013
NDA 204822 (label) INN (TRAVOPROST) IZBA (NOVARTIS) APPROVAL= AP YEAR= 2014 DISCONTINUED
NDA 203431 (pdf not found) INN (TRAVOPROST) TRAVOPROST (APOTEX) APPROVAL= AP YEAR= 2015
NDA 205050 (pdf not found) INN (TRAVOPROST) TRAVOPROST (MYLAN) APPROVAL= AP YEAR= 2017
NDA 210458 (pdf not found) INN (TRAVOPROST) TRAVOPROST (ALEMBIC) APPROVAL= AP YEAR= 2019 DISCONTINUED
NDA 203767 (pdf not found) INN (TRAVOPROST) TRAVOPROST (MICRO LABS) APPROVAL= AP YEAR= 2021
NDA 218010 (label) INN (TRAVOPROST) IDOSE TR (GLAUKOS) APPROVAL= AP YEAR= 2023
NDA 207040 (pdf not found) INN (TRAVOPROST) TRAVOPROST (LUPIN) APPROVAL= AP YEAR= 2024 DISCONTINUED
NDA 217228 (pdf not found) INN (TRAVOPROST) TRAVOPROST (SOMERSET THERAPS LLC) APPROVAL= AP YEAR= 2024
NDA 218159 (pdf not found) INN (TRAVOPROST) TRAVOPROST (GLAND) APPROVAL= AP YEAR= 2024
NDA 214687 (pdf not found) INN (TRAVOPROST) TRAVOPROST (ALEMBIC) APPROVAL= AP YEAR= 2025

Other links:

PubChem
ChemicalProbes

U.S. repository of Clinical Trials

VigiAccess
SIDER side effects

ChemSynthesis
Patent@SureChEMBL